Reviewing Todos Med (OTCMKTS:TOMDF) & Auna (NYSE:AUNA)

Auna (NYSE:AUNA) and Todos Med (OTCMKTS:TOMDF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Risk and Volatility

Auna has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Todos Med has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Auna and Todos Med, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auna	1	1	1	2	2.80
Todos Med	0	0	0	0	0.00

Auna presently has a consensus target price of $7.30, suggesting a potential upside of 26.93%. Given Auna’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Auna is more favorable than Todos Med.

Profitability

This table compares Auna and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auna	2.13%	19.23%	4.70%
Todos Med	N/A	N/A	N/A

Earnings & Valuation

This table compares Auna and Todos Med”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auna	$1.23 billion	0.35	$27.39 million	$0.36	15.98
Todos Med	N/A	N/A	N/A	N/A	N/A

Auna has higher revenue and earnings than Todos Med.

Summary

Auna beats Todos Med on 9 of the 9 factors compared between the two stocks.

About Auna

Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.